NovaBiotics Overview
- Year Founded
-
2004
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Later Stage VC
- Investors
-
4
NovaBiotics General Information
Description
Operator of a clinical-stage biotechnology company intended to develop therapies to treat medically unmet diseases. The company's therapies focus on the development of antibacterial and antifungal candidates for the treatment of invasive fungal diseases caused by mold and emerging drug-resistant yeasts, enabling researchers to study antifungal peptides in development to prevent and treat life-limiting inflammatory, infectious, and respiratory diseases.
Contact Information
Website
www.novabiotics.co.ukCorporate Office
- ONE BioHub, Foresterhill Road
- Aberdeen AB25 2XE
- Scotland, United Kingdom
Corporate Office
- ONE BioHub, Foresterhill Road
- Aberdeen AB25 2XE
- Scotland, United Kingdom
NovaBiotics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC | Completed | Generating Revenue | ||||
| 10. Secondary Transaction - Private | 01-Feb-2021 | Completed | Generating Revenue | |||
| 9. Grant | 16-Oct-2020 | Completed | Generating Revenue | |||
| 8. Grant | 19-Mar-2019 | Completed | Generating Revenue | |||
| 7. Grant | 01-Jan-2019 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 03-Mar-2017 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 19-Jan-2015 | Completed | Startup | |||
| 4. Later Stage VC | 14-Mar-2012 | Completed | Startup | |||
| 3. Later Stage VC | 25-Nov-2011 | $9.5M | $9.5M | Completed | Startup | |
| 2. Grant | 10-Sep-2009 | $361K | Completed | Startup |
NovaBiotics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary 7 | ||||||||
| Ordinary 6 | ||||||||
| Ordinary 5 | ||||||||
| Ordinary A | ||||||||
| Ordinary 4 | ||||||||
| Ordinary 3 | ||||||||
| Ordinary 2 | 2,043,642 | $0.158951 | $1.2 | $1.2 | 1x | $1.2 | 19.4% | |
| Ordinary 1 | 1,400,368 | $0.158951 | $1.19 | $1.19 | 1x | $1.19 | 13.3% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
NovaBiotics Comparisons
Industry
Financing
Details
NovaBiotics Competitors (43)
One of NovaBiotics’s 43 competitors is Venatorx Pharmaceuticals, a Venture Capital-Backed company based in Malvern, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Venatorx Pharmaceuticals | Venture Capital-Backed | Malvern, PA | ||||
| Eligo Bioscience | Venture Capital-Backed | Paris, France | ||||
| Seres Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX | ||||
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA |
NovaBiotics Patents
NovaBiotics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202418321-D0 | Next generation delivery of antimicrobial peptides | Inactive | 13-Dec-2024 | ||
| AU-2025206098-A1 | Compositions to improve the condition and/or appearance of keratinised tissue | Pending | 05-Jan-2024 | ||
| EP-4836752-A1 | Compositions to improve the condition and/or appearance of keratinised tissue | Pending | 05-Jan-2024 | ||
| WO-2025146549-A1 | Compositions to improve the condition and/or appearance of keratinised tissue | Inactive | 05-Jan-2024 | ||
| GB-202400182-D0 | Improved compositions to improve the appearance and/or condition of skin, scalp, nail and/or hair | Inactive | 05-Jan-2024 | A61K8/88 |
NovaBiotics Signals
NovaBiotics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| U.K. Department of Health & Social Care | Government | Minority | ||
| Innovate UK | Government | |||
| University College London | University | |||
| Acacia Research | Corporation | Minority |
NovaBiotics FAQs
-
When was NovaBiotics founded?
NovaBiotics was founded in 2004.
-
Where is NovaBiotics headquartered?
NovaBiotics is headquartered in Aberdeen, United Kingdom.
-
What is the size of NovaBiotics?
NovaBiotics has 15 total employees.
-
What industry is NovaBiotics in?
NovaBiotics’s primary industry is Biotechnology.
-
Is NovaBiotics a private or public company?
NovaBiotics is a Private company.
-
What is NovaBiotics’s current revenue?
The current revenue for NovaBiotics is .
-
How much funding has NovaBiotics raised over time?
NovaBiotics has raised $35.9M.
-
Who are NovaBiotics’s investors?
U.K. Department of Health & Social Care, Innovate UK, University College London, and Acacia Research have invested in NovaBiotics.
-
Who are NovaBiotics’s competitors?
Venatorx Pharmaceuticals, Eligo Bioscience, Seres Therapeutics, Rein Therapeutics, and Vedanta Biosciences are some of the 43 competitors of NovaBiotics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process